Evidence map›Paper›PMID 32315817›Full record

SynthesisJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2020

Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis.

Yong Hu, Jiazhong Sun, Zhe Dai, Haohua Deng, Xin Li, Qi Huang, Yuwen Wu, Li Sun, Yancheng Xu

2 registry-linked trialsOpen access · greenAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 304 papers, 25 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
304citing papers in PubMed, 25 pooled it
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04631536 phase3unknown statusnot on this mapstarted 2021, after this paper: background citation

Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at the Lebanese American University Medical Center- Rizk Hospital

TypeinterventionalSponsorLebanese American University Medical CenterRan2021 to 2022Enrolled42ConditionsCovid19ArmsAtorvastatin + L-arginine + Folic acid + Nicorandil + Nebivolol, Placebo
NCT04716985 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Evaluation of the Daily Intake of 0.5 L of Water Saturated With Molecular Hydrogen for 21 Days in COVID-19 Patients Treated in Ambulatory Care. Double-blind, Randomized, Comparative Study

TypeinterventionalSponsorAGIR à DomRan2021 to 2023Enrolled700ConditionsSARS-CoV-2, Covid19, AMBULATORY CAREArmsMOLECULAR HYDROGEN, PLACEBO MAGNESIUM
3 · Its place in the literature

Who cites it

304 citing papers in PubMed, 25 syntheses or guidelines pooled it, 748 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

244 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yong HuDepartment of Endocrinology, Zhongnan Hospital of Wuhan University, No 167, Donghu Road, Wuchang District, Wuhan 430000, China.
Jiazhong SunDepartment of Endocrinology, Zhongnan Hospital of Wuhan University, No 167, Donghu Road, Wuchang District, Wuhan 430000, China.
Zhe DaiDepartment of Endocrinology, Zhongnan Hospital of Wuhan University, No 167, Donghu Road, Wuchang District, Wuhan 430000, China.
Haohua DengDepartment of Endocrinology, Zhongnan Hospital of Wuhan University, No 167, Donghu Road, Wuchang District, Wuhan 430000, China.
Xin LiDepartment of Endocrinology, Zhongnan Hospital of Wuhan University, No 167, Donghu Road, Wuchang District, Wuhan 430000, China.
Qi HuangDepartment of Endocrinology, Zhongnan Hospital of Wuhan University, No 167, Donghu Road, Wuchang District, Wuhan 430000, China.
Yuwen WuDepartment of Endocrinology, Zhongnan Hospital of Wuhan University, No 167, Donghu Road, Wuchang District, Wuhan 430000, China.
Li SunDepartment of Endocrinology, Zhongnan Hospital of Wuhan University, No 167, Donghu Road, Wuchang District, Wuhan 430000, China.
Yancheng XuDepartment of Endocrinology, Zhongnan Hospital of Wuhan University, No 167, Donghu Road, Wuchang District, Wuhan 430000, China. Electronic address: xjl100901@whu.edu.cn.
Wuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince being first reported in Wuhan, China, in December 8, 2019, the outbreak of the novel coronavirus, now known as COVID-19, has spread globally. Some case studies regarding the characteristics and outcome of patients with COVID-19 have been published recently. We conducted a meta-analysis to evaluate the risk factors of COVID-19.

methodsMedline, SinoMed, EMBASE, and Cochrane Library were searched for clinical and epidemiological studies on confirmed cases of COVID-19.

resultsThe incidence of fever, cough, fatigue, and dyspnea symptoms were 85.6 % (95CI 81.3-89.9 %), 65.7 % (95CI 60.1-71.4 %), 42.4 % (95CI 32.2-52.6 %) and 21.4 % (95CI 15.3-27.5 %). The prevalence of diabetes was 7.7 % (95CI 6.1-9.3 %), hypertension was 15.6 % (95CI 12.6-18.6 %), cardiovascular disease was 4.7 % (95CI 3.1-6.2 %), and malignancy was 1.2 % (95CI 0.5-1.8 %). The complications, including ARDS risk, ranged from 5.6-13.2 %, with the pooled estimate of ARDS risk at 9.4 %, ACI at 5.8 % (95CI 0.7-10.8 %), AKI at 2.1 % (95CI 0.6-3.7 %), and shock at 4.7 % (95CI 0.9-8.6 %). The risks of severity and mortality ranged from 12.6 to 23.5% and from 2.0 to 4.4 %, with pooled estimates at 18.0 and 3.2 %, respectively. The percentage of critical cases in diabetes and hypertension was 44.5 % (95CI 27.0-61.9 %) and 41.7 % (95CI 26.4-56.9 %), respectively.

conclusionFever is the most common symptom in patients with COVID-19. The most prevalent comorbidities are hypertension and diabetes which are associated with the severity of COVID-19. ARDS and ACI may be the main obstacles for patients to treatment recovery. The case severe rate and mortality is lower than that of SARS and MERS.

Indexed as

BetacoronavirusChinaComorbidityCoronavirus InfectionsCoughCOVID-19Diabetes ComplicationsFeverHumansHypertensionIncidencePandemicsPneumonia, ViralPrevalenceRisk FactorsSARS-CoV-2ComorbiditiesCOVID-19MortalitySeveritySymptom

Identifiers

PMID32315817
PMCPMC7195434
OpenAlexW3017183898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.